deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT02282345

Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer

A Pilot Study of Talazoparib as a Neoadjuvant Study in Patients With a Diagnosis of Invasive Breast Cancer and a Deleterious BRCA Mutation

Sponsor: M.D. Anderson Cancer Center

Conditions Breast Adenocarcinoma Deleterious BRCA1 Gene Mutation Deleterious BRCA2 Gene Mutation HER2/Neu Negative Invasive Breast Carcinoma
Interventions Laboratory Biomarker Analysis Talazoparib
Updated 16 times since 2017 Last updated: Jun 16, 2022 Started: Apr 16, 2015 Primary completion: Apr 26, 2018 Completion: Jun 7, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02282345, this PHASE2 trial focuses on Breast Adenocarcinoma and Deleterious BRCA1 Gene Mutation and remains completed. Sponsored by M.D. Anderson Cancer Center, it has been updated 16 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Dec 2017 · 8 months · monthly snapshot~Dec 2017 – ~Jan 2018 · 31 days · monthly snapshot~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshot~Jun 2018 – ~Feb 2019 · 8 months · monthly snapshot~Feb 2019 – ~Jun 2019 · 4 months · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Sep 2019 · 2 months · monthly snapshot~Sep 2019 – ~Sep 2020 · 12 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Mar 2022 · 14 months · monthly snapshot~Mar 2022 – ~Sep 2022 · 6 months · monthly snapshot~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Sep 2022 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  4. Mar 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE2

  5. Jan 2021 — Mar 2022 [monthly]

    Active Not Recruiting PHASE2

▶ Show 11 earlier versions

  1. Sep 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  2. Sep 2019 — Sep 2020 [monthly]

    Active Not Recruiting PHASE2

  3. Jul 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE2

  4. Jun 2019 — Jul 2019 [monthly]

    Active Not Recruiting PHASE2

  5. Feb 2019 — Jun 2019 [monthly]

    Active Not Recruiting PHASE2

  6. Jun 2018 — Feb 2019 [monthly]

    Active Not Recruiting PHASE2

  7. Jan 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  8. Dec 2017 — Jan 2018 [monthly]

    Recruiting PHASE2

  9. Apr 2017 — Dec 2017 [monthly]

    Recruiting PHASE2

  10. Feb 2017 — Apr 2017 [monthly]

    Recruiting PHASE2

  11. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Apr 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • M.D. Anderson Cancer Center
  • National Cancer Institute (NCI)
Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations